Glaucoma is one of the most common causes of permanent blindness. Even if patients regulate their intraocular pressure with today’s gold standard treatment techniques, the disease progresses for most of the patients and causes the permanent blindness and this is irreversible. Recent studies show that glaucoma is actually not only an eye disease but also it affects the brain that creates neurodegeneration. Most of the current treatment techniques focus only lowering the intraocular pressure ignoring the neurodegenerative side of glaucoma. GlaucoT develops a novel wearable noninvasive neuroprotective glaucoma treatment device to reduce neuroinflammation in brain.
Our GlaucoT digital platform offers a unique innovation, providing ground-breaking advantages with the potential to revolutionize glaucoma management. GlaucoT platform for gamma waves entrainment is comprised of the treatment device and the connected mobile application for the comprehensive digital home-based treatment. Multiple studies demonstrated that neuroprotection by sensory stimuli provides significant neuroprotection. We take advantage of an emerging gamma wave entrainment therapy that has demonstrated positive results in Alzheimer’s Disease (AD) patients and in aging mice retina. AD and glaucoma share common pathogenic neurodegenerative pathways in the eye and the brain; and aging is also a risk factor for glaucoma. Our device, GlaucoT, applies the flickering light for visual stimulation to provide neuroprotection in the retina and other tissues of the visual pathway. Therefore, the progression to a later stage of glaucoma and blindness could be delayed or completely prevented.
Several achievements have been accomplished since our cofounders had the idea of implementing recent discoveries on the neuroprotective effect of gamma waves entrainment on Alzheimer’s disease to glaucoma. The innovation at the heart of the technology is the neuroprotective flickering-light wearable goggles with a smart application for gamma waves entrainment in glaucoma. We patented the technology, developed lab prototypes, and verified them in the lab environment. We have performed a safety study and have been performing an exploratory study to validate our clinical prototype’s efficacy and safety with promising preliminary results. In parallel, we have initiated a randomized controlled trial (RCT) in Turkey. First outcomes of our clinical study show promising results, as increased electrophysiological activity on the full visual path from retina to visual cortex.
The GlaucoT positions itself as a mission driven company aiming to prevent physical and socioeconomic effects of Glaucoma worldwide, as it is a common disease among elderly people over 40 years old. Our mission is to provide a healthy life with a good vision (sight) at all ages for diagnosed patients.